source
- AbbVie’s HS drug lutikizumab meets Phase 3 goal but falls short of analyst expectationsAbbVie reported that its investigational IL‑1α/β inhibitor lutikizumab achieved the primary endpoint in the Phase 3 INTREPID study for hidradenitis suppurativa, a chronic inflammatory skin disease…
- U.S. proposes rule tightening review of biotech licensing deals with Chinese firmsThe U.S. is preparing to issue a proposed rule that would place additional scrutiny on outbound licensing agreements between American biotech firms and Chinese companies. The measure aims to increa…